Order Article Reprints

Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon J-C, et al. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. International Journal of Molecular Sciences. 2021; 22(15):8017. https://doi.org/10.3390/ijms22158017

Reschke, Robin, Philipp Gussek, Andreas Boldt, Ulrich Sack, Ulrike Köhl, Florian Lordick, Thomas Gora, Markus Kreuz, Kristin Reiche, Jan-Christoph Simon, and et al. 2021. "Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy" International Journal of Molecular Sciences 22, no. 15: 8017. https://doi.org/10.3390/ijms22158017

Reschke, R., Gussek, P., Boldt, A., Sack, U., Köhl, U., Lordick, F., Gora, T., Kreuz, M., Reiche, K., Simon, J. -C., Ziemer, M., & Kunz, M. (2021). Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy. International Journal of Molecular Sciences, 22(15), 8017. https://doi.org/10.3390/ijms22158017